letolizumab

Letolizumab (BMS-986004) is a humanized monoclonal antibody and dimeric fusion protein that functions as an antagonist of the CD40 ligand (CD40L). It is designed to bind specifically to CD40L expressed on activated T lymphocytes, thereby inhibiting the interaction between CD40L and its receptor CD40. This blockade modulates immune activation and has been investigated primarily for its potential in preventing acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation. Letolizumab was developed by Bristol Myers Squibb in collaboration with H. Lee Moffitt Cancer Center and Research Institute[1][3][7][8]. The drug has also been studied for idiopathic thrombocytopenic purpura (ITP), but no recent development has been reported for this indication[3][5].

Other names

letolizumabanti-CD40L Fc-fusion protein BMS-986004anti-CD-40L Fc-fusion protein BMS-986004anti-CD 40L Fc-fusion protein BMS-986004